• The design of coronary stents continues to evolve to reduce short-and long-term adverse events
Parameter

Conclusions
• Lower ppMI rates of BP-SES translate into meaningful reductions in direct medical cost, amounting to about 10% of the cost of a drug-eluting stent [8] , while improving patient outcomes
• Most of the cost reduction is attributed to the initial admission with moderate savings up to 12 months post-discharge
Limitations
• As with all simulation studies, our findings are suggestive and in need of confirmatory empirical research
• Although we make several assumptions related to the structure and content of our model, we base all assumptions on empirical evidence augmented with expert opinion and our results are robust to different assumptions as demonstrated by our sensitivity analyses
Implications
• Our findings suggest that the ultrathin, bioresorbable polymer sirolimus-eluting stent is an attractive option for patients undergoing percutaneous coronary intervention from a population health and economic perspective
• The results should help clinicians, payers and purchasers in making future decisions about the choice of coronary stents. Additional research is needed to establish the improvement in cost and clinical outcomes past the 12 months covered by the current data
Sensitivity analyses results
• In the univariate analysis, assumptions for differential ppMI rates have the largest effect on the predicted benefit, followed by the midpoint assumption for the attributed cost during the index admission 
